1315 Capital has completed the acquisition of Argonaut Manufacturing Services’ life sciences and diagnostics division, for undisclosed terms. The acquired division will operate independently as Aluris Sciences with 1315 Capital supporting its continued growth and investment. The transaction involved the LSDx division only; ownership of Argonaut remains with Telegraph Hill Partners, New Vale Capital and management.

Argonaut is a contract development and manufacturing organization specializing in aseptic fill-finish of high value injectable biologics and pharmaceuticals. Aluris Sciences, the newly independent entity, provides manufacturing solutions spanning formulation, filling, kitting, lyophilization, assembly, packaging and supply chain management, supporting customers from pilot-stage programs through clinical, validation and commercial production. Argonaut confirmed that all existing drug product program timelines, quality commitments and contractual obligations remain unchanged, with clients continuing to work with the same team at the same Carlsbad, California facilities.

No drug product programs, assets or regulatory filings were included in the transaction. KPMG Corporate Finance served as Argonaut’s exclusive financial advisor on the transaction. 1315 Capital is a Philadelphia-based private investment firm with over $1 billion of assets under management, providing growth capital to commercial-stage healthcare services, pharmaceutical & medtech outsourced services, and health & wellness companies.